<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889236</url>
  </required_header>
  <id_info>
    <org_study_id>P17.249</org_study_id>
    <nct_id>NCT03889236</nct_id>
  </id_info>
  <brief_title>Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.</brief_title>
  <acronym>Glycotreat</acronym>
  <official_title>The Effect of Dietary Interventions on Endothelial Glycocalyx Dimensions and Barrier Function in South Asian Patients With Diabetic Nephropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Holland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of a fasting mimicking diet and a food supplement on the microvascular
      health and urinary heparanase levels in South Asian type 2 diabetic patients with
      albuminuria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized into the diet group, food supplement group or placebo group. The placebo and foodsupplement groups are double blinded.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The placebo and food supplement groups are double blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) in the fasting mimicking diet or food supplement group compared to the placebo</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in urinary heparanase levels in the fasting mimicking diet or food supplement group compared to the placebo</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in urinary MCP-1 levels in the fasting mimicking diet or food supplement group compared to the placebo</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetic Nephropathy Type 2</condition>
  <condition>Albuminuria</condition>
  <condition>Type2 Diabetes Mellitus</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Microalbuminuria</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Diabetic Complications Renal</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Kidney Diseases</condition>
  <condition>South Asian</condition>
  <arm_group>
    <arm_group_label>Fasting mimicking diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules a day of the food supplement Endocalyx for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules a day of the placebo for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting mimicking diet Prolon</intervention_name>
    <description>5-day fasting mimicking diet</description>
    <arm_group_label>Fasting mimicking diet</arm_group_label>
    <other_name>FMD</other_name>
    <other_name>Prolon</other_name>
    <other_name>L-Nutra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Food supplement Endocalyx</intervention_name>
    <description>Food supplement</description>
    <arm_group_label>Food supplement</arm_group_label>
    <other_name>Endocalyx</other_name>
    <other_name>Q-prime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. South Asian patient with diabetes mellitus type 2.

          2. Female or male, aged between 18 and 75 years.

          3. Body Mass Index ≥18.5.

          4. CKD-EPI &gt;45 ml/min/1.73m² .

          5. Proven microalbuminuria defined as albumin/creatinine ratio ≥0.3 and &lt;30 mg/mmol
             (single portion) or 3-300 mg albumin per day (24 hours urine collection) in the last
             twelve months.

          6. Systolic blood pressure ≤ 180 mmHg.

          7. Treatment with hypoglycemic drugs: metformin, sulphonylureas and/or insulin.

          8. Subject is willing to participate in the study, must be able to give informed consent
             and the consent must be obtained prior to any study procedure.

          9. Patients must be able to adhere to the study visit schedule and protocol requirements.

         10. If female and of child-bearing age, patients must be non-pregnant, non-breastfeeding,
             and use adequate contraception.

        4.3 Exclusion

        Exclusion Criteria:

          1. Any concurrent illness, disability or clinically significant abnormality that may, as
             judged by the investigator, affect the interpretation of clinical efficacy or safety
             data or prevent the subject from safely completing the assessments required by the
             protocol.

          2. Non-diabetic renal disease e.g. known polycystic kidney disease.

          3. Use of LMW heparin and/or immunosuppressive drugs.

          4. Significant food allergies for galactose, nuts, soy, tomato, corn, grape, melon and
             artichoke, which would make the subject unable to consume the food provided.

          5. Signs of active infection or autoimmune disease, requiring systemic treatment.

          6. A psychiatric, addictive or any disorder that compromises ability to give truly
             informed consent for participation in this study.

          7. Malignancy (including lymphoproliferative disease) within the past 2-5 years (except
             for squamous or basal cell carcinoma of the skin that has been treated with no
             evidence of recurrence).

          8. Use of any other investigational drug.

          9. Patient has enrolled another clinical trial within last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ton J. Rabelink, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anouk I.M. van der Velden, Msc.</last_name>
    <phone>+31 (0)71- 5296907</phone>
    <email>A.I.M.van_der_Velden@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daphne H.T. Ijpelaar, Dr.</last_name>
    <email>D.H.T.Ijpelaar@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden Universitiy Medical Center (LUMC)</name>
      <address>
        <city>Leiden</city>
        <state>Noord Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anouk I.M. van der Velden, Msc</last_name>
      <phone>+31 (0)71- 5296907</phone>
      <email>a.i.m.van_der_velden@lumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>AnoukvanderVelden</investigator_full_name>
    <investigator_title>Msc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03889236/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

